Sustained reductions in weight and HbA_1c with dapagliflozin: long-term results from phase III clinical studies in type 2 diabetes

Medicine & Life Sciences

• 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol 100%
• Weight Loss 52%
• Type 2 Diabetes Mellitus 48%
• Clinical Studies 44%
• Metformin 30%
• Placebos 19%
• Body Weight 17%
• Insulin 12%
• Glipizide 10%
• Sodium-Glucose Transporter 2 Inhibitors 10%
• Symporters 9%
• Glucose 6%
• Overweight 6%
• Reproductive Tract Infections 5%
• Blood Pressure 4%
• Phase III Clinical Trials 4%
• Insulin Secretion 3%
• Hypoglycemia 3%
• Urinary Tract Infections 3%
• Weight Gain 3%
• Creatinine 2%
• Clinical Trials 2%
• Infections 1%
• Population 1%
• Therapeutics 0%